Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Carien L. Creutzberg"'
Autor:
Carien L. Creutzberg, Petronella B. Ottevanger, Annamaria Ferrero, Luis Souhami, Pearly Khaw, GH Westerveld, Diane Provencher, Gillian Thomas, Jan Pyman, V. Do, Annerie Slot, C Davidson, G. Wilson, Stephanie M. de Boer, Peter Hoskin, C M McLachlin, Michael A. Quinn, Deborah Gregory, Remi A. Nout, Hans W. Nijman, J.J. Jobsen, Tanja C. Stam, Vincent T.H.B.M. Smit, K Whitmarsh, Paul Bessette, Roy F.P.M. Kruitwagen, W Taylor, Dionyssios Katsaros, Chantal Hanzen, Henry C Kitchener, M McCormack, Prafull Ghatage, Dominique Berton-Rigaud, J.W.M. Mens, Melanie E Powell, Elisabeth Pras, Jonathan A. Ledermann, Karen W Verhoeven-Adema, Harmen Hollema, Andrea Lissoni, Linda Mileshkin, Anjana Anand, Amanda Feeney, Sergio Gribaudo, Marie-Helene Baron, R Allerton, Hein Putter, Colin D. Johnson, P. Symonds, Ina M. Jürgenliemk-Schulz, Romerai D'Amico, Ilka Kolodziej, M Adusumalli, Naveena Singh, G Artioli, An Snyers, R Wade, Christine Haie-Meder, Roldano Fossati, Nicole Tubiana-Mathieu, Anthony Fyles, Silvestro Carinelli, Anne Capp, Alexandra J. Stewart, Kaj De Winter, B. van Triest, L.C.H.W. Lutgens, Susan Brooks, E. Van der Steen-Banasik, Pierre Duvillard, Pvc Rittenberg, Alessandro Colombo
Publikováno v:
Lancet Oncology, 20, 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
BACKGROUND:The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and